Biotechnology movers and shakers on the move. Read new hires, promotions of executives, and more.
Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.
As Executive Chairman, Robert Bitterman will assume the duties of principal executive officer and principal financial officer and will lead all aspects of the Company's operations.
“It is a pleasure to welcome both Jennifer and Adnan to the RAPT leadership team at this exciting time of growth for the Company,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “The combination of their regulatory, commercial and marketing expertise is invaluable as we advance our RPT193 program into late stage trials in atopic dermatitis and asthma and continue development of FLX475 program in multiple cancer indications.”
Christoper Prentiss joins ADARx as ADX-324 for the treatment of hereditary angioedema is set to start phase I clinical trials at the end of the year. ADARx has two additional drug candidates set to enter clinical trials next year and an extensive pipeline to follow.
Epiphany Technology Acquisition Corp. notes the Board appointed Mr. Ross Haghighat as Co-Chief Executive Officer of the Company.
In addition to serving as interim CEO, Ms. Curley will remain CFO. The iSpecimen Board of Directors (the “Board”) is currently reviewing the Company’s near- and long-term needs pertaining to the role of Chief Executive Officer.